Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

被引：0

作者：

Mirallas, O. ^{[1
]}

Marmolejo Castaneda, D. H. ^{[1
]}

Illescas, D. G. ^{[1
]}

Gomez-Puerto, D. ^{[2
]}

Berche, R. ^{[3
,4
]}

Calvo, A. H. ^{[5
]}

Vieito Villar, M. ^{[2
]}

Lorini, L. ^{[6
]}

Navarro, V. ^{[4
,7
]}

Assaf Pastrana, J. D. ^{[8
]}

Saavedra, O. ^{[9
]}

Alonso, G. ^{[10
]}

Aguilar Izquierdo, S. ^{[11
]}

Bescos, C. ^{[12
]}

Lorente, J. ^{[13
]}

Giralt, J. ^{[14
]}

Dienstmann, R. ^{[15
]}

Garralda, E. ^{[16
]}

Felip, E. ^{[17
]}

Brana, I. ^{[1
]}

机构：

[1] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[2] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] Cellex Ctr, Barcelona, Spain

[5] Princess Margaret Canc Ctr, Med Oncol Phase Unit 1, Toronto, ON, Canada

[6] Azienda Osped Spedali Civili Brescia, Dipartimento Oncol Med, Brescia, Italy

[7] Vall dHebron Inst Oncol VHIO, Odyssey Grp, Barcelona, Spain

[8] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain

[9] Vall dHebron Univ Hosp, Res Unit Mol Therapy Canc UITM, Barcelona, Spain

[10] Vall dHebron Inst Oncol, Early Drug Dev Unit, Barcelona, Spain

[11] Vall dHebron Univ Hosp, Mol Prescreening Program Dept, Barcelona, Spain

[12] Vall dHebron Univ Hosp, Maxillofacial & Oral Surg, Barcelona, Spain

[13] Vall dHebron Univ Hosp, Otorhinolaryngol Dept, Barcelona, Spain

[14] Vall dHebron Univ Hosp, Radiotherapy Dept, Barcelona, Spain

[15] Grp Oncoclin, Oncol Data Sci Dept, Sao Paulo, Brazil

[16] Vall dHebron Univ Hosp, Early Drug Dev Grp, Barcelona, Spain

[17] Vall dHebron Univ Hosp, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.810

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

686P

引用

页码：S856 / S857

页数：2

共 50 条

[21] Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Alkhatib, Hosam H.
Maroun, Christopher A.
Amin, Neha
Zhu, Gangcai
Guller, Meytal
Herberg, Matthew E.
Wu, Evan S.
Seiwert, Tanguy Y.
Rooper, Lisa M.
Eisele, David W.
Fakhry, Carole
Pardoll, Drew
Mandal, Rajarsi
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (06) : 540 - 546
[22] Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Vidales Sepulveda, Z.
Choulli, M.
Fabrego, S.
Pallares, N.
Santos, N.
Llop Serna, S.
Brenes Castro, J.
Plana Serrahima, M.
Juarez Lozano, C. M.
Brunet, A.
Melero, M.
Bermejo, O.
Vilajosana, E.
Godino, C.
Oliva, M.
Arribas, L.
ANNALS OF ONCOLOGY, 2023, 34 : S585 - S586
[23] Circulating tumor DNA kinetics in recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) patients
Taylor, K.
Zou, J.
Burgener, J.
Zhao, E.
Torti, D.
Oliva, M.
Spreafico, A.
Hansen, A. R.
Jang, R.
McDade, S. S.
Coyle, V. M.
Lawler, M.
Elimova, E.
Bratman, S. V.
Siu, L. L.
ANNALS OF ONCOLOGY, 2021, 32 : S796 - S797
[24] Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck
Recchia, Francesco
Candeloro, Giampiero
Di Staso, Mario
Necozione, Stefano
Bisegna, Roberta
Bratta, Massimo
Tombolini, Vincenzo
Rea, Silvio
JOURNAL OF IMMUNOTHERAPY, 2008, 31 (04) : 413 - 419
[25] Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study
Muratori, L.
Texier, M.
Mayache-Badis, L.
Bidault, F.
Iacob, M.
Daste, A.
Fayette, J.
Lefebvre, G.
Saada-Bouzid, E.
Zanetta, S.
Toullec, C.
Cupissol, D.
Salas, S.
Kaminsky-Forrett, M-C.
Johnson, A. C.
Ferrand, F. R.
Auperin, A.
Guigay, J.
Raynard, B.
Even, C.
ANNALS OF ONCOLOGY, 2021, 32 : S809 - S810
[26] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Bauman, J. E.
ANNALS OF ONCOLOGY, 2018, 29
[27] Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study
Even, C.
Bernard-Tessier, A.
Texier, M.
Said, O. Ben
Iacob, M.
Daste, A.
Fayette, J.
Zanetta, S.
Lefebvre, G.
Vinches, M.
Johnson, A. C.
Le Moal, L. Bozec
Saada, E. B.
Jallut, I.
Garic, F.
Monard, L.
Bourhis, J.
Guigay, J.
Auperin, A.
Ammari, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S851 - S851
[28] Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)
Jose Echarri, Maria
Lopez-Martin, Ana
Hitt, Ricardo
CANCERS, 2016, 8 (03)
[29] A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
Mousa, L.
Issa, M.
Klamer, B.
Pan, J.
Old, M.
Kang, S.
Agrawal, A.
Ozer, E.
Carrau, R.
Bhateja, P.
Rupert, R.
Jhawar, S.
Mitchell, D.
Gamez, M.
Rocco, J.
Blakaj, D.
Bonomi, M. R.
ANNALS OF ONCOLOGY, 2019, 30
[30] Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.
Carulla, Yannick
Neidhardt, Eve-Marie
Karabajakian, Andy
Gauduchon, Thibault
Guevara, Hemerson
Roux, Pierre Eric
Zrounba, Philippe
Podeur, Fabien
Poupart, Marc
Excoffier, Aude
Fayette, Jerome
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →